Patients With Hodgkin Lymphoma May Develop Third Malignancy
Hodgkin lymphoma survivors who have developed a second malignancy are at a higher risk of developing a third malignancy.
Diagnosis & Disease Information
Beleodaq Earns FDA Approval for Peripheral T-cell Lymphoma
The FDA has approved Beleodaq for the treatment of patients with peripheral T-cell lymphoma.
Clinical Surveillance Possible in Classical Hodgkin Lymphoma After Remission
Survival rate for patients who underwent clinical surveillance was similar those who underwent routine surveillance imaging.
New Routine Testing for Non-Hodgkin Lymphomas Recommended
Three subgroups of a single type of non-Hodgkin lymphoma have different survival rates.
Oral Arsenic-based Regimen for Relapsed/Refractory Mantle Cell Lymphoma
Patients with relapsed/refractory mantle cell lymphoma may benefit from an oral arsenic-based treatment regimen.
Proton Therapy May Be Safe for Hodgkin Lymphoma
Post-chemotherapy proton therapy has a similar success rate to more conventional methods.
Elderly Men May Need Higher Rituximab Dose for DLBCL
Research presented at ASCO 2014 shows that elderly men with DLBCL have lesser responses to standard therapy compared to elderly women.
MRI Catches Breast Cancer Early in Hodgkin Lymphoma Survivors
The largest clinical study to evaluate breast cancer screening of female survivors of childhood Hodgkin lymphoma, showed that MRI detected invasive breast tumors at very early stages, when cure rates are expected to be excellent.
Time to Progression Worse in Nodular Lymphocyte-predominant Hodgkin Lymphoma
Risk for relapse and splenic involvement are higher in patients with advanced-stage nodular lymphocyte-predominant Hodgkin lymphoma compared with patients with classical Hodgkin lymphoma.
Monocyte/Lymphocyte Ratio Predicts Outcomes in DLBCL
Absolute lymphocyte count to absolute monocyte count ratio may be have prognostic utility in patients with relapsed or primary refractory diffuse large B-cell lymphoma, new data suggest.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...